Precision Medicine in Oncology® | Specialty

Dual Pathways Must Be Targeted in ER-Positive Breast Cancer

January 4th 2013

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Going Off-Label: It's Time to Ponder the Nature of Sufficient Evidence

January 4th 2013

In the absence of a phase III randomized trial, what constitutes sufficient evidence to justify use of a treatment, particularly a nontraditional treatment or one that challenges common practice?

Searching for New Pathways and Treatments for Head and Neck Squamous Cell Carcinoma

December 27th 2012

Scientists now know a lot more about the genetic landscape of head and neck cancer and hope that eventually this knowledge will lead the way to new therapies.

Cristi Radford on Utilizing Gene Panels in Ovarian Cancer

December 20th 2012

Cristi Radford, MS, CGC, from the Sarasota Memorial Hospital, discusses examining cancer gene panels using next generation sequencing for patients with ovarian cancer.

Dr. Cortes on the Phase II Ponatinib PACE Trial

December 12th 2012

Jorge E. Cortes, MD, from the MD Anderson Cancer Center, describes results from a 12 month follow up of the phase II PACE study that examined ponatinib in patients with CML and Ph+ ALL.

Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer

December 12th 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the administration of dacomitinib for patient with EGFR-positive lung cancer.

Gaining Ground: Personal Losses Help Drive Pioneer in Stem Cell Study

December 12th 2012

An interview with Jenny C. Chang, MB BChir, MD, who broke new ground in cancer research when she identified and patented a 493-gene signature for breast cancer.

Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers

December 11th 2012

Predictive biomarkers are beginning to help physicians assign value to associated therapies in terms of likelihood of benefit and benefit-to-risk profiles for individual patients.

Justin Balko on the Diversity of Genetic Alterations in TNBC

December 8th 2012

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

December 6th 2012

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

December 5th 2012

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

December 5th 2012

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

EGFR Mutation Status Might Predict Sorafenib Benefit in NSCLC

November 30th 2012

Results of the phase III MISSION trial showed that third- or fourth-line treatment with sorafenib did not improve overall survival in patients with advanced non–small cell lung cancer.

Taking a Look at Four Noteworthy Studies

November 28th 2012

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

Peering Deeper Into the Black Box

November 28th 2012

Over the past decade, there has been an explosion of knowledge regarding the fundamental drivers of the malignant phenotype.

Dr. Weitzel on Combination Therapies in Breast Cancer

November 26th 2012

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment

November 19th 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

Molecular and Personalized Medicine in Breast Cancer

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part II

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part I

November 15th 2012